Prognosis of Lung Adenocarcinoma Patients With NTRK3 Mutations to Immune Checkpoint Inhibitors

BACKGROUND: Immune checkpoint inhibitors (ICIs) are an important treatment modality that must be considered for patients with lung adenocarcinoma (LUAD). However, ICIs are effective only in some of these patients. Therefore, identifying biomarkers that accurately predict the prognosis of patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Niu, Yuchun, Lin, Anqi, Luo, Peng, Zhu, Weiliang, Wei, Ting, Tang, Ruixiang, Guo, Linlang, Zhang, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7434857/
https://www.ncbi.nlm.nih.gov/pubmed/32903385
http://dx.doi.org/10.3389/fphar.2020.01213

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7434857/
https://www.ncbi.nlm.nih.gov/pubmed/32903385
http://dx.doi.org/10.3389/fphar.2020.01213

Ejemplares similares